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The coincidence of autoantibodies against the acetylcholine receptor (AChR) and muscle
striational antigens (SA) is a characteristic finding in thymoma-associated myasthenia
gravis (MG), but their origins are still unresolved. Some common muscle antigens that
were shown to be targets of anti-SA autoantibodies in thymoma-associated MG have
also been detected in normal or neoplastic th)fmic epithelial cells, suggesting that the
release of (eventually altered) antigens from the thymic tumors Could elicit SA
autoimmunity. In contrast to this model, we report here that titin, which is a recently
reported target of SA autoimmunity, is not expressed in thymomas. In addition, we
show that skeletal muscle type-II fibers exhibit a striational immunoreactivity with
monoclonal antibody mAb155, which was previously identified to label a very
immunogenic cytoplasmic epitope of the AChR and neoplastic epithelial cells of MG-
associated thymomas. We conclude from these findings that titin autoimmunity in
thymoma-associated MG is either due to a molecular mimicry mechanism involving
tumor antigens (other than titin) or is a secondary phenomenon following release of titin
from muscle. Based on the common immunoreactivity of the AChR, a striational antigen
and thymoma, we suggest as the pathogenetic mechanism of thymoma-associated MGa
"circulus vitiosus" in which SA autoimmunity could help maintain the AChR
autoimmunity that is primarily elicited by the thymomas.
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INTRODUCTION
Myasthenia gravis (MG) is characterized by an
abnormal fatiguability of muscle produced in
most patients by autoantibodies against the nic-
otinic acetylcholine receptor (AChR). These auto-
antibodies are thought to impair neuromuscular
transmission by reducing the number of muscle
endplate AChR or blocking their function
(Drachman, et al., 1980; Burges et al., 1990)
In addition to anti-AChR autoimmunity, 70%
of MG patients exhibit thymitis with or without
*Corresponding author: Present address: Pathologisches Insti-
tut der Universit/it, Josef Schneider Str. 2, 8700 W(irzburg,
Germany.
lymphofollicular hyperplasia (M(iller-Hermelink
et al., 1986; Kirchner et al., 1986) and 10% have a
thymoma (Kirchner and MiJller-Hermelink,
1989). As an important diagnostic feature, only
the latter group of MG patients almost invariably
has high titers of heterogeneous autoantibodies
against striational muscle antigens (SA) in
addition to anti-AChR autoantibodies (Peers et
al., 1977; Aarli et al., 1990; Connor et al., 1990;
Ohta et al., 1990). In thymoma patients without
MG anti-SA autoantibodies occur in only 24%
(Williams and Lennon, 1987).
How SA autoimmunity is elicited in thymomas
is not known. However, the finding that myosin
and some less well-defined muscle proteins are
anti-SA-autoantibody targets that also occur in
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normal or neoplastic thymic epithelial cells
(Gilhus et al., 1984; Williams and Lennon, 1987;
Dardenne et al., 1987) has led to the hypothesis
that thymomas might be the sites of SA autosen-
sitization. Because an antigenic relationship
between striational antigens and the AChR was
not known, it is obscure whether autoimmune
reactions against SA and AChR are interrelated.
Recently, titin was identified as a major target
of anti-SA autoantibodies in MG (Aarli et al.,
1990). In the present paper, we report that titin is
not expressed in thymomas, suggesting that this
kind of SA autoimmunity is either not due to
intratumorous autosensitization or occurs by
molecular mimicry mechanisms, that is, by titin-
related antigenic determinants in thymoma pro-
teins that may cross-react with titin-"specific" T
cells, which could induce an antititin autoanti-
body response when released to the periphery. In
addition, an immunoreactivity is demonstrated
that is shared by the AChR alpha subunit and a
striational antigen different from titin. Because
the respective epitopemcorresponding to AChR
alpha371-378mis the only one so far detected in
MG-associated thymomas, we suggest that AChR
autoimmunity and part of SA autoimmunity in
MG-associated thymomas could be interrelated.
RESULTS
Titin Is Expressed in Thymic Myoid Cells but
Not in Thymomas
Frozen sections of two normal thymuses were
probed with antititin mAb to three different titin
epitopes. As shown in Fig. 1, immunoreactivity
with all three mAbs was seen in a few round or
spindle-shaped cells inside the medulla of nor-
mal thymuses close to Hassal’s corpuscles. Both
the localization and the morphology of these, cells
are typical of thymic myoid cells (Kirchner et al.,
1988). This was confirmed by double immuno-
labeling of thymic myoid cells by both antide-
smin or anti-AChR mAb and by antititin mAbT12
(Figs. 2a and 2b). There was no expression of titin
in keratin-positive nonneopalstic thymic epi-
thelial cells (Fig. 2c).
Because of the high incidence of antititin auto-
antibodies typical of MG/thymoma patients
(Aarli et al., 1990), we looked for an aberrant
expression of titin in thymoma because the de-
novo expression of other proteins has previously
been reported as a typical feature of neoplastic
thymic epithelium (Willcox et al., 1987; Marx et
al., 1990, 1991). However, with respect to the
FIGURE 1. Immunoreactivity of a few round or spindle-shaped cells inside the human thymic medulla with antititin
monoclonal antibodies T4 (a), T12 (b), and T32 (c). Morphology and localization are typical of thymic myoid cells (cf. Fig. 2). No
immunoreactivity is encountered in epithelial cells. Immunoperoxidase technique on frozen sections (x160).STRIATIONAL AChR-EPITOPE IN MYASTHENIA 81
FIGURE 4. Immunoreactivity of a striational muscle antigen in about 50% of quadriceps muscle fibers with anti-AChR mAb155
directed against the AChR epitope alpha371-378 (a). No reactivity of muscle with anti-AChR mAb195 directed against the AChR
"main immunogenic region" (Tzartos et al., 1983) (b). In contrast to the striational immunoreactivity of mAb155, the
immunoreactivity with antititin mAb T12 is encountered in 100% of muscle fibers (c), demonstrating the nonidentity of titin and
the AChR-epitope-bearing striational antigen in human quadriceps muscle (all sections #$361). Frozen sections,
immunoperoxidase (x400).
FIGURE 5. Immunoreactivity of
anti-AChR mAb155 with a stri-
ational antigen is confined to type-II
fibers in the quadriceps muscle. Ser-
ial cross sections labeled with
mAb155 (a; immunoperoxidase) and
reacted for ATPase activity at pH
9.4 (b). Immunoreactivity with
mAb155 coincides with a high
ATPase activity (dark color) typical
of type-II fibers (Dubowitz, 1985) (x
400).
have to prove whether the striational antigen
immunolabeled by mAb155 (Fig. 4a) is identical
to the thymoma proteins bearing the AChR epi-
tope detected by mAb 155 (Marx et al., 1989,82 A. MARX et al.
TABLE
Clinical and Pathological Findings inMG Patients with
Thymic Epithelial Tumors and in Controls
Case No. Sex Age (y) Histologic AChR
diagnosis Epitope
19964 F 34 Mixed thymoma
29117 F 64 Mixed thymoma
15977 F 76 Cortical thymoma +
6942 M 50 Cortical thymoma +
22401 F 63 Well-differentiated +
thymic carcinoma
27920 M 45 Well-differentiated +
thymic carcinoma
Thy2 F 2 Normal thymus +b
Thy40 M 40 Normal thymus +b
$361 M 2 Quadriceps muscle +c
$64 F 81 Quadriceps muscle +c
aImmunoreactivity with anti-AChR mAb155 (Tzartos et al., 1986).
bImmunoreactivity of mAb155 with thymic myoid cells and medullary epi-
thelial cells (Kirchner and Mtiller-Hermelink, 1989).
cStriational pattern in type-II fibers.
1990), and whether either molecule is in fact a
target of autoimmune B or T cells in vivo. If the
latter question could be positively answered, our
finding suggests a pathogenetic model in which
striational autoimmunity might help to maintain
AChR autoimmunity. Such a model of a "circulus
vitiosus" would explain the clinical experience
that removal of the thymoma does not ameliorate
the MG.
and normal quadriceps muscle (obtained from
autopsies within 6 hr after death) were investi-
gated using cryostat sections from snap frozen
tissue. Tumors were classified according to
Kirchner and Mi.iller-Hermelink (1990). Clinical
data of patients are summarized in Table 1.
The diagnosis of generalized myasthenia
gravis was based on clinical findings, including
an abnormal muscle fatiguability, electrophysio-
logical investigations and anti-AChR serum titers
that were above I nmol/L.
Immunohistochemistry
The monoclonal antibodies (mAb) used in this
study are described in Table 2. The immunohisto-
chemical three-stage immunoperoxidase tech-
nique and the double-labeling procedure com-
bining the immunoperoxidase with an alkaline
phosphatase technique (as the first and second
step, respectively) were as described previously,
including the same control experiments
(Kirchner et al., 1988).
Muscle Fiber-Type Determination
MATERIALS AND METHODS
Patients and Tissues
Six thymomas from MG patients, two normal
thymuses (obtained during thoracic surgery),
To investigate whether skeletal muscle immuno-
reactivity with anti-AChR mAb155 was confined
to either type-I or -II muscle fibers serial frozen
sections were processed for routine enzyme
histochemical determination of ATPase activity
at both pH 4.6 and pH 9.4 (Dubowitz, 1985).
TABLE 2
Antibodies Used in This Study
Antibody Concentration or
dilution applied
Antigen labeled Source
35betaH11 1:100
Desmin 1:1000
T4 1:50
T12 1:10
T32 1:5
mAb155 tg/mL
mAb195 tg/mL
Keratin No. 8/18
Desmin
Nonrepetitive titin epitope inside the band
Nonrepetitive titin epitope close to the Z line
Repetitive titin epitope within the A band
AChR-epitope alpha371-378
AChR-epitope alpha67-76 (MIRa)
Gown and Vogel, 1982
Laboserv Giessen, Germany
Ftirst et al., 1988
Fiirst et al., 1988
F(irst et al., 1989
Tzartos et al., 1986
Tzartos et al., 1988
aMIR=main immunogenic region (Tzartos et al., 1988).STRIATIONAL AChR-EPITOPE IN MYASTHENIA 83
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